Share on StockTwits

Cara Therapeutics (NASDAQ:CARA) released its earnings data on Thursday. The company reported ($0.16) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.27) by $0.11, Stock Ratings Network.com reports. The company had revenue of $0.96 million for the quarter, compared to the consensus estimate of $0.08 million. Cara Therapeutics’s revenue was down 90.4% compared to the same quarter last year.

On a related note, analysts at Canaccord Genuity raised their price target on shares of Cara Therapeutics from $25.00 to $29.00 in a research note on Thursday, May 15th. Four analysts have rated the stock with a buy rating, Cara Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $25.00.

Cara Therapeutics (NASDAQ:CARA) traded down 6.49% during mid-day trading on Thursday, hitting $10.80. 71,590 shares of the company’s stock traded hands. Cara Therapeutics has a one year low of $10.40 and a one year high of $23.25. The stock’s 50-day moving average is $14.22 and its 200-day moving average is $15.13. The company’s market cap is $244.1 million.

Cara Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors.

Receive News & Ratings for Cara Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.